We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Definium Therapeutics, Inc.는 임상 바이오 제약 회사로, 뇌 건강 질환 치료를 위한 혁신적인 신약 후보 물질을 개발합니다. 이 회사의 주요 신약 후보 물질로는 범불안장애, 주요 우울장애 및 기타 뇌 건강 질환 치료를 위해 임상 3상 단계에 있는 DT120과, 3,4-methylenedioxymethamphetamine의 R-이성질체로 자폐 스펙트럼 장애 치료를 위해 임상 2a상 시험 단계에 있는 DT402가 있습니다. 이 회사는 이전에 Mind Medicine (MindMed) Inc.로 알려져 있었으며, 2026년 1월 Definium Therapeutics, Inc.로 사명을 변경했습니다. Definium Therapeutics, Inc.는 뉴욕주 뉴욕에 본사를 두고 있습니다.